How The Midwest Was Won: Creating A New Epicenter For Device Innovation And Investment

Talent, innovation, world-class research institutions, established supply chains, and a lower cost of doing business – what else do you need to launch and grow a device company? Well, capital, for one. Players in the Midwest are working in a variety of ways to draw entrepreneurs and venture money to the region, and their efforts are reaping positive results.

The American Midwest brings to mind images of vast, fertile fields of wheat, corn, and other important crops, but its significance is now much more than agricultural. The often unassuming US heartland – comprising Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin – is also a fast-growing hotbed for medical device research and development, entrepreneurship, and investment. With industry-leading manufacturers such as Medtronic PLC, St. Jude Medical Inc., Hologic Inc., GE Healthcare/General Electric Co., Cook Group Inc., Boston Scientific Corp., 3M Co., DePuy Orthopaedics Inc./Johnson & Johnson, Biomet Inc., and Zimmer Biomet Holdings Inc. headquartered in the Midwest, the region has long been known for developing and manufacturing a wide variety of advanced implantable devices and imaging technologies. In fact, DePuy, Biomet, and Zimmer alone comprise one-third of the world's orthopedics industry, according to Indiana life sciences accelerator BioCrossroads. And, with its established outsourcing and supply chains, world-class research universities, including Case Western Reserve University and the University of Wisconsin, Madison, a large talent pool, and lower cost of doing business, the Midwest is turning out to be fertile soil indeed for device entrepreneurs launching a new venture.

A critical component for start-up success, however, is financing, and although the Midwest has traditionally been underserved and overlooked by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

NAD Alerts Agendia Over Endorsing Physician’s Ties To Firm

 
• By 

The National Advertising Division (NAD) alerted Agendia to improve disclosure regarding a physician endorsing its MammaPrint test. The physician's ties to Agendia were inadequately revealed in LinkedIn posts.

FDA Ends Effort To Regulate LDTs By Rescinding Final Rule

 

Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.

Exact Sciences’ Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By 

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

More from North America

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By 

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

Warning Letters - July 2025

The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.

Survey Reveals Gaps In Medtech Compliance Processes

 
• By 

Medical device firms often have serious compliance gaps, a recent Veeva MedTech survey found. Only 50% of the companies surveyed are confident in their global registration data, with 70% reporting inconsistencies during audits. The report recommends automation and better data governance.